Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Global Clinical Trials Review, H2, 2015 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/b756tw/acute_myelocytic) has announced the addition of the "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015" report to their offering.

"Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Global Clinical Trials Review, H2, 2015" provides an overview of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).

Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Key Topics Covered:

  1. Report Guidance
  2. Clinical Trials by Region
  3. Clinical Trials and Average Enrollment by Country
  4. Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  5. Top Five Countries Contributing to Clinical Trials in Europe
  6. Top Countries Contributing to Clinical Trials in North America
  7. Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  8. Top Five Countries Contributing to Clinical Trials in Central and South America
  9. Clinical Trials by G7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
  10. Clinical Trials by Phase in G7 Countries
  11. Clinical Trials in G7 Countries by Trial Status
  12. Clinical Trials by E7 Countries: Proportion of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) to Oncology Clinical Trials
  13. Clinical Trials by Phase in E7 Countries
  14. Clinical Trials in E7 Countries by Trial Status
  15. Clinical Trials by Phase
  16. In Progress Trials by Phase
  17. Clinical Trials by Trial Status
  18. Clinical Trials by End Point Status
  19. Unaccomplished Trials of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
  20. Subjects Recruited Over a Period of Time
  21. Clinical Trials by Sponsor Type
  22. Prominent Sponsors
  23. Top Companies Participating in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Therapeutics Clinical Trials
  • Celgene Corporation
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline Plc
  • AstraZeneca Plc

For more information visit http://www.researchandmarkets.com/research/b756tw/acute_myelocytic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Clinical Trials, Hematology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Clinical Trials, Hematology